Form 4: Zenas BioPharma CFO/CBO Jennifer Fox Granted 150,000 Stock Options

Jennifer A. Fox, Chief Financial Officer and Chief Business Officer of Zenas BioPharma, Inc., was granted 150,000 stock options at an exercise price of $11.94 per share.

Summary

• Jennifer A. Fox, the Chief Financial Officer and Chief Business Officer of Zenas BioPharma, Inc. (ZBIO), was granted 150,000 stock options.
• The stock options have an exercise price of $11.94 per share.
• The options begin vesting on June 10, 2026, with 25% of the underlying shares vesting on this first anniversary of the vesting commencement date.
• The remaining shares will vest in equal monthly installments over the subsequent 36 months.
• Vesting is contingent upon continued service to the company.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Jennifer A. Fox beneficially owns 150,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management retention and alignment of interests with shareholders, though it is a routine compensation disclosure.

Positives

• The grant of stock options to a key executive like the CFO/CBO aligns her interests with those of the shareholders, incentivizing long-term performance and value creation.
• This compensation structure is a common practice to attract and retain senior talent in the biotechnology industry.

Future Outlook

The vesting schedule of the stock options, extending over four years, implies an expectation of continued service from Jennifer A. Fox, aligning her long-term commitment with the company's strategic objectives.

Industry Context

The granting of stock options to key executives is a standard compensation practice within the biotechnology and pharmaceutical industries, designed to incentivize long-term performance, retain talent, and align management's financial interests with shareholder value creation. This particular grant is consistent with typical executive incentive structures in growth-oriented biotech firms.

Comparison to Industry Standards

• The exercise price of $11.94 per share is consistent with the market price at the time of grant, which is a standard practice for incentive stock options.
• The four-year vesting schedule (25% on first anniversary, then monthly over 36 months) is a common industry standard for executive equity grants, balancing immediate incentive with long-term retention.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the interests of a key executive with shareholder value creation, potentially leading to improved long-term performance.
• Employees: This transaction highlights the company's approach to executive compensation, which may influence broader employee incentive programs.

Next Steps

• Jennifer A. Fox's continued service to Zenas BioPharma, Inc. is required for the vesting of the granted stock options.

Key Dates

Keywords

Zenas BioPharma, ZBIO, Stock Options, Executive Compensation, Insider Transaction, Jennifer A. Fox, Form 4, Biotechnology